Comment on: Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials

Br J Surg. 2024 Apr 3;111(4):znae085. doi: 10.1093/bjs/znae085.

Authors

Patrick W Underwood¹, Jordan M Cloyd¹

Affiliation

¹ Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

No abstract available

MeSH terms

Adenocarcinoma*
Antineoplastic Combined Chemotherapy Protocols
Carbohydrates / therapeutic use
Chemoradiotherapy
Humans
Neoadjuvant Therapy / adverse effects
Pancreatectomy / adverse effects
Pancreatic Neoplasms* / surgery
Randomized Controlled Trials as Topic

Substances

Carbohydrates